James Lisa M, Georgopoulos Apostolos P
Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, 55417, USA.
Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
J Neurol Neuromedicine. 2019 Sep 9;4(5):1-6. doi: 10.29245/2572.942x/2019/5.1253.
Human Leukocyte Antigen (HLA) Class II DRB113 alleles have recently been found to protect against age-related brain deterioration, even in the presence of apolipoprotein E4 (apoE4), suggesting a possible protection against dementia. Here we evaluated the association between the population frequency of common DRB113 alleles and the prevalence of dementia in Continental Western Europe. Prevalence of dementia in Continental Western Europe was derived from published reports on dementia frequency from the Global Burden of Disease Study 2016 and population totals obtained from the Population Reference Bureau. DRB113:01 and DRB113:02 allele frequencies were obtained from a publicly available database (allelefrequency.net) and apolipoprotein E was obtained from published reports on the world distribution of apoE4. The prevalence of dementia in 14 Continental Western European (CWE) countries, where life expectancy is practically identical, significantly decreases exponentially with increasing frequency of DRB113:02 (R = 0.452, P = 0.008), even when adjusted for the prevalence of apolipoprotein E4 allele, a known risk factor for Alzheimer's disease. This finding documents the protective effect of DRB113:02 on dementia prevalence in CWE. Since the function of HLA class II genes is to aid in the elimination of pathogens by enabling the production of antibodies against their antigens in specific immunity, the protective effect of DRB113:02 points to the presence of persistent harmful antigens as causal factors in development of dementia, antigens specific to DRB113:02 that could not be eliminated in its absence.
人类白细胞抗原(HLA)II类DRB113等位基因最近被发现可预防与年龄相关的脑功能衰退,即使在存在载脂蛋白E4(apoE4)的情况下也是如此,这表明其可能对痴呆症具有预防作用。在此,我们评估了常见DRB113等位基因的人群频率与西欧大陆痴呆症患病率之间的关联。西欧大陆痴呆症的患病率来自《2016年全球疾病负担研究》中关于痴呆症发病率的已发表报告以及从人口参考局获得的人口总数。DRB113:01和DRB113:02等位基因频率来自一个公开可用的数据库(allelefrequency.net),载脂蛋白E则来自关于apoE4全球分布的已发表报告。在预期寿命几乎相同的14个西欧大陆(CWE)国家中,痴呆症的患病率随着DRB113:02频率的增加而呈指数显著下降(R = 0.452,P = 0.008),即使在对载脂蛋白E4等位基因的患病率进行调整后也是如此,载脂蛋白E4等位基因是阿尔茨海默病的一个已知风险因素。这一发现证明了DRB113:02对CWE中痴呆症患病率的保护作用。由于HLA II类基因的功能是通过在特异性免疫中产生针对病原体抗原的抗体来帮助消除病原体,DRB113:02的保护作用表明存在持续的有害抗原作为痴呆症发展的因果因素,即DRB113:02特异性的抗原,在其不存在时无法被消除。